Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RPRX's Cash to Debt is ranked higher than
96% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. RPRX: No Debt )
RPRX' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: No Debt

Equity to Asset 0.95
RPRX's Equity to Asset is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RPRX: 0.95 )
RPRX' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.99
Current: 0.95

0.09
0.99
Interest Coverage No Debt
RPRX's Interest Coverage is ranked higher than
99% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RPRX: No Debt )
RPRX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 37.51
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -353077.78
RPRX's Operating margin (%) is ranked lower than
53% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. RPRX: -353077.78 )
RPRX' s 10-Year Operating margin (%) Range
Min: -624550   Max: -101.1
Current: -353077.78

-624550
-101.1
Net-margin (%) -353077.78
RPRX's Net-margin (%) is ranked lower than
53% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. RPRX: -353077.78 )
RPRX' s 10-Year Net-margin (%) Range
Min: -624550   Max: -35.93
Current: -353077.78

-624550
-35.93
ROE (%) -46.88
RPRX's ROE (%) is ranked higher than
69% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. RPRX: -46.88 )
RPRX' s 10-Year ROE (%) Range
Min: -336.72   Max: -2.72
Current: -46.88

-336.72
-2.72
ROA (%) -44.55
RPRX's ROA (%) is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. RPRX: -44.55 )
RPRX' s 10-Year ROA (%) Range
Min: -237.27   Max: -2.17
Current: -44.55

-237.27
-2.17
ROC (Joel Greenblatt) (%) -49651.56
RPRX's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. RPRX: -49651.56 )
RPRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -136170   Max: -226.32
Current: -49651.56

-136170
-226.32
Revenue Growth (3Y)(%) -100.00
RPRX's Revenue Growth (3Y)(%) is ranked higher than
54% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. RPRX: -100.00 )
RPRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 183.2
Current: -100

0
183.2
EBITDA Growth (3Y)(%) 31.50
RPRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. RPRX: 31.50 )
RPRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -51.7   Max: 68.7
Current: 31.5

-51.7
68.7
EPS Growth (3Y)(%) 31.10
RPRX's EPS Growth (3Y)(%) is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. RPRX: 31.10 )
RPRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -59   Max: 112.8
Current: 31.1

-59
112.8
» RPRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

RPRX Guru Trades in Q3 2013

Steven Cohen 2,603 sh (+85.93%)
» More
Q4 2013

RPRX Guru Trades in Q4 2013

Steven Cohen Sold Out
» More
Q2 2014

RPRX Guru Trades in Q2 2014

Steven Cohen 100,268 sh (unchged)
» More
Q3 2014

RPRX Guru Trades in Q3 2014

John Paulson 1,000,000 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-09-30 New Buy0.04%$8.77 - $22.16 $ 9.15-38%1000000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.93
RPRX's P/B is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. RPRX: 3.93 )
RPRX' s 10-Year P/B Range
Min: 0.7   Max: 85
Current: 3.93

0.7
85
P/S 21163.95
RPRX's P/S is ranked higher than
51% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. RPRX: 21163.95 )
RPRX' s 10-Year P/S Range
Min: 10.55   Max: 941.67
Current: 21163.95

10.55
941.67
EV-to-EBIT -5.32
RPRX's EV-to-EBIT is ranked higher than
64% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RPRX: -5.32 )
RPRX' s 10-Year EV-to-EBIT Range
Min: -31.1   Max: 0.5
Current: -5.32

-31.1
0.5
Current Ratio 17.93
RPRX's Current Ratio is ranked higher than
94% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. RPRX: 17.93 )
RPRX' s 10-Year Current Ratio Range
Min: 0.23   Max: 66.45
Current: 17.93

0.23
66.45
Quick Ratio 17.93
RPRX's Quick Ratio is ranked higher than
94% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. RPRX: 17.93 )
RPRX' s 10-Year Quick Ratio Range
Min: 0.23   Max: 66.45
Current: 17.93

0.23
66.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.22
RPRX's Price/Net Cash is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. RPRX: 4.22 )
RPRX' s 10-Year Price/Net Cash Range
Min: 0.45   Max: 84.15
Current: 4.22

0.45
84.15
Price/Net Current Asset Value 4.22
RPRX's Price/Net Current Asset Value is ranked higher than
91% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. RPRX: 4.22 )
RPRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 533.33
Current: 4.22

0.44
533.33
Price/Tangible Book 4.19
RPRX's Price/Tangible Book is ranked higher than
84% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. RPRX: 4.19 )
RPRX' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 100.57
Current: 4.19

0.42
100.57
Earnings Yield (Greenblatt) -18.80
RPRX's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. RPRX: -18.80 )
RPRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 217.9   Max: 41501.3
Current: -18.8

217.9
41501.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ZONN.Germany,
Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main product candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company's second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.
» More Articles for RPRX

Headlines

Articles On GuruFocus.com
comment on RPRX Mar 06 2013 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
promotes testosteron Jun 22 2011 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
How To Profit From The Obesity Epidemic Dec 08 2014
REPROS THERAPEUTICS INC. Financials Nov 15 2014
10-Q for Repros Therapeutics, Inc. Nov 12 2014
Brean Capital Sees No Surprises In 3Q14 Report For Repros Therapeutics Nov 11 2014
Repros Soars on Positive FDA Meeting Regarding Androxa Nov 10 2014
Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results Nov 10 2014
Repros Therapeutics posts 3Q loss Nov 10 2014
Repros Therapeutics posts 3Q loss Nov 10 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 10 2014
Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results Nov 10 2014
Q3 2014 Repros Therapeutics Inc Earnings Release - Before Market Open Nov 10 2014
Another lackluster session for major equities Nov 07 2014
Sears Soars Nearly +40% As REIT News Boosts Confidence Nov 07 2014
Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal Nov 07 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events Nov 06 2014
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing Nov 06 2014
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing Nov 06 2014
Will Repros (RPRX) Miss Estimates This Earnings Season? Nov 05 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 31 2014
Repros to Webcast Investor and Analyst Day on October 31st Oct 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK